Company profile
LifeMD, Inc.
NASDAQ: LFMD · Healthcare · Medical - Pharmaceuticals
#293 of 1,418 Healthcare companies by revenue33rd-percentile growth
EA Score
73BFH 76DQ 79GM 50SS 73
v0.1 · 65/100 weight · provisional
↑ return on equity, return on assets · ↓ revenue growth (YoY), balance-sheet leverage
Methodology →Revenue TTM
$219.4M
Rev growth YoY (TTM)
-6.2%
Net income (FY)
$14.4M
Employees
350
as of 2026-08-13
Market cap
$159.1M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$194.1M$194.1M2025
Net income$14.4M$14.4M2025
Operating income-$7.7M-$7.7M2025
Total assets$70.4M$70.4M2025
Liabilities$47.3M$47.3M2025
Equity$23.2M$23.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product and Services100%
By geography
Not disclosed.
The read
What is LifeMD, Inc.’s revenue?
LifeMD, Inc. booked $194.1M in FY2025 revenue, contracting 8.7% year over year — slower than 67% of Healthcare companies we track, at a 7.4% net margin.
Peers · Healthcare
Cytek Biosciences, Inc.58CSI-BONE, Inc.70BStrata Critical Medical, Inc.60Cbiote Corp.63CRhythm Pharmaceuticals, Inc.60CMaravai LifeSciences Holdings, Inc.53DNeighbors
New York →Key facts
CEOJustin Schreiber
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersNew York City, NY
ExchangeNASDAQ: LFMD
Employees350
IPO date2008-01-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.